-
公开(公告)号：US20170056366A1
公开(公告)日：2017-03-02
申请号：US15245448
申请日：2016-08-24
IPC分类号： A61K31/351 , A61K47/10 , A61K9/08
CPC分类号： A61K31/351 , A61K9/0095 , A61K9/08 , A61K47/10
摘要： The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.
摘要翻译： 以及制造这种液体药物组合物及其医疗用途的相应方法。
-
公开(公告)号：US20240307628A1
公开(公告)日：2024-09-19
申请号：US18594627
申请日：2024-03-04
IPC分类号： A61M5/315 , A61K31/7048
CPC分类号： A61M5/31513 , A61K31/7048
摘要： Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.
-
公开(公告)号：US20230381101A1
公开(公告)日：2023-11-30
申请号：US18321117
申请日：2023-05-22
发明人： Claudius WEILER , Thomas Adam DUCH
IPC分类号： A61K9/08 , A61K31/7004 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K47/32 , A61K47/10 , A61K47/12 , A61K47/02 , A61K47/26 , A61K47/46 , A61K47/20 , A61K31/7034
CPC分类号： A61K9/08 , A61K31/7004 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K47/32 , A61K47/10 , A61K47/12 , A61K47/02 , A61K47/26 , A61K47/46 , A61K47/20 , A61K31/7034
摘要： The invention relates to novel aqueous pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more solubilizing agents as well as corresponding processes of manufacturing such aqueous pharmaceutical compositions and their medical uses.
-
-
搜索结果
3 条记录 (耗时 0.013 秒)
